| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.2M | +88.2% | -48.2% |
| SG&A Expense | $1.1M | -15.0% | -23.7% |
| Operating Income | -$3.3M | -35.0% | +42.2% |
| Net Income | -$3.2M | -35.5% | +42.6% |
| EPS (Basic) | -$5.76 | +10.3% | -2204.0% |
| EPS (Diluted) | -$5.76 | +10.3% | -2204.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $9.9M | -18.7% | +41.5% |
| Current Assets | $11.4M | -19.4% | +54.2% |
| Total Assets | $11.9M | -18.2% | +60.2% |
| Current Liabilities | $2.0M | +41.7% | -51.7% |
| Total Liabilities | $2.0M | +41.7% | -51.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$10.8M | — | — |
| Financing Cash Flow | $14.2M | — | — |
| $9.9M |
| -24.5% |
| +195.6% |